Alice Chung
Alice Chung
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Breast Cancer
Axillary Nodal Disease
Female Breast Cancer
Axilla; Breast
Mastectomy; Lymphedema
Tumor, Breast
Breast Surgery (BCS or mastectomy) with TAD/SNB
Adjuvant Radiation Therapy
PHASE2
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 45 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients with Clinical T1-2N0 ER+ Her2- Breast Cancer with Ultrasound Detected Nodal Metastases |
| Actual Study Start Date : | 2024-04-07 |
| Estimated Primary Completion Date : | 2031-04 |
| Estimated Study Completion Date : | 2031-04 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 45 Years |
| Sexes Eligible for Study: | FEMALE |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California, United States, 90048
RECRUITING
CS Cancer at Huntington Cancer Center
Pasadena, California, United States, 91105
RECRUITING
CS Cancer at Valley Oncology Medical Group
Tarzana, California, United States, 91356